Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTACT: [225Ac]Ac-FL-020 in mCRPC
NCT06492122Phase 1Recruiting
- Sponsor
- Full-Life Technologies
- Start
- Aug 2024
- Primary completion
- Oct 2026
- Modality
- Radiopharmaceutical
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-FL-020 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Full-Life Technologies. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events. Started Aug 2024; status: recruiting.
02
Drugs
225Ac-FL-020
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06492122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492122.